Literature DB >> 34260815

Potential of C-X-C motif chemokine ligand 1/8/10/12 as diagnostic and prognostic biomarkers in idiopathic pulmonary arterial hypertension.

Zhenhua Li1, Jie Jiang1, Shan Gao1.   

Abstract

OBJECTIVE: This study aimed to evaluate the clinical role of C-X-C motif chemokine ligand (CXCL) family members in idiopathic pulmonary arterial hypertension (IPAH) patients.
METHODS: CXCL1, CXCL8, CXCL10 and CXCL12 expressions in the serum samples of IPAH patients (N = 39) and age-/gender-matched controls (N = 40) were detected by enzyme-linked immunosorbent assay. In IPAH patients, clinical features were collected, and survival information was documented.
RESULTS: CXCL1 (P < 0.001), CXCL8 (P = 0.001), CXCL10 (P < 0.001) and CXCL12 (P < 0.001) were increased in IPAH patients compared with controls, and receiver's operating characteristic curves showed that their combination was highly correlated with IPAH risk (area under curve: 0.881, 95% confidence interval: 0.805-0.958). Meanwhile, CXCL1 was positively correlated with mean pulmonary artery pressure (mPAP) (P = 0.029) and high-sensitive C-reactive protein (HsCRP) (P = 0.015); CXCL8 was positively correlated with mPAP (P = 0.044) and HsCRP (P = 0.018) but negatively correlated with 6-minute walk test (6MWT) distance (P = 0.029); CXCL10 was positively correlated with mean right artery pressure (P = 0.002); and CXCL12 was positively correlated with World Health Organization functional class (P = 0.047), mPAP (P = 0.009), pulmonary vascular resistance (P = 0.004) and HsCRP (P = 0.003) but negatively correlated with 6MWT distance (P = 0.003) in IPAH patients. Moreover, CXCL12 was negatively correlated with overall survival (OS) (P = 0.025), whereas CXCL1, CXCL8 and CXCL10 only showed minor tendencies to be negatively correlated with OS in IPAH patients without statistical significance (all P > 0.05).
CONCLUSION: CXCL1, CXCL8, CXCL10 and CXCL12 associate with increased IPAH risk, unfavourable clinical features; besides, CXCL12 correlates with worse OS in IPAH patients.
© 2021 The Authors. The Clinical Respiratory Journal published by John Wiley & Sons Ltd.

Entities:  

Keywords:  C-X-C motif chemokine ligand; clinical features; idiopathic pulmonary arterial hypertension; overall survival; predictive value

Mesh:

Substances:

Year:  2021        PMID: 34260815     DOI: 10.1111/crj.13421

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  3 in total

1.  Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation.

Authors:  Ratoe Suraya; Tatsuya Nagano; Gusty Rizky Teguh Ryanto; Wiwin Is Effendi; Daisuke Hazama; Naoko Katsurada; Masatsugu Yamamoto; Motoko Tachihara; Noriaki Emoto; Yoshihiro Nishimura; Kazuyuki Kobayashi
Journal:  Respir Res       Date:  2022-06-27

2.  Integrated Bioinformatic Analysis Reveals TXNRD1 as a Novel Biomarker and Potential Therapeutic Target in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Wenchao Lin; Yiyang Tang; Mengqiu Zhang; Benhui Liang; Meijuan Wang; Lihuang Zha; Zaixin Yu
Journal:  Front Med (Lausanne)       Date:  2022-05-12

3.  The alterations in molecular markers and signaling pathways in chronic thromboembolic pulmonary hypertension, a study with transcriptome sequencing and bioinformatic analysis.

Authors:  Wenqing Xu; Mei Deng; Xiapei Meng; Xuebiao Sun; Xincao Tao; Dingyi Wang; Shuai Zhang; Yanan Zhen; Xiaopeng Liu; Min Liu
Journal:  Front Cardiovasc Med       Date:  2022-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.